AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Arcutis Biotherapeutics, Inc.
Video analysis: ARQT
All videosNo video analysis for this stock yet. Request one from our team.
News: ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York.
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT
Bamco Inc. NY acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,253,120 shares of the company's stock, valued at approximately $32,857,000. Bamco Inc. NY owned
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG
Deutsche Bank AG bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 382,682 shares of the company's stock, valued at approximately $10,034,000. Deutsche Bank AG owned approximately 0.31% of Arcutis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis' common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis' common stock to 24 newly hired employees.
